AHA26: Pelacarsen misses primary endpoint in Phase III HORIZON trial
HORIZON's disappointing results raise questions about the future of Lp(a)-lowering therapies, but the wider pipeline offers hope.
HORIZON's disappointing results raise questions about the future of Lp(a)-lowering therapies, but the wider pipeline offers hope.